Anti-Glomerular Basement Membrane Antibody Disease

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Hansa Biopharma
Hansa BiopharmaSweden - Lund
1 program
1
ImlifidasePhase 21 trial
Active Trials
NCT03157037CompletedEst. Jul 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Hansa BiopharmaImlifidase

Clinical Trials (1)

Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease

Start: Jun 2017Est. completion: Jul 2020
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space